Cite

HARVARD Citation

    Sanoff, H. et al. (2018). Multicenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer. Cancer. 124 (15), pp. 3118-3126. [Online]. 
  
Back to record